AVCNF (Avicanna) Gross-Profit-to-Asset % : 72.08% (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Avicanna Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Avicanna's annualized Gross Profit for the quarter that ended in Sep. 2024 was $10.54 Mil. Avicanna's average Total Assets over the quarter that ended in Sep. 2024 was $14.62 Mil. Therefore, Avicanna's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 was 72.08%.

Avicanna Gross-Profit-to-Asset % Historical Data

The historical data trend for Avicanna's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avicanna Gross-Profit-to-Asset % Chart

Avicanna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

0.24

-1.54

10.80

5.40

33.82

Avicanna Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															48.48	29.59	54.83	56.00	72.08

Competitive Comparison of Avicanna's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Avicanna's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avicanna's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avicanna's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Avicanna's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

Avicanna Gross-Profit-to-Asset % Calculation

Avicanna's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	4.963	/	( (12.969	+	16.377)	/ 2 )
	=	4.963	/	14.673
	=	33.82 %

Avicanna's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
	=	10.54	/	( (14.131	+	15.114)	/ 2 )
	=	10.54	/	14.6225
	=	72.08 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Sep. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Avicanna Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Avicanna's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Avicanna Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avicanna Inc (OTCPK:AVCNF) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

0NN:Germany AVCN:Canada

Address

480 University Avenue, Suite 1502, Toronto, BC, CAN, M5G 1V2

Website

https://www.avicanna.com

Avicanna Inc is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In global cannabinoid advancements, it conducts most of its research in Canada at its research and development headquarters in JLABS in Toronto, located in the MaRS Discovery District. The company actively collaborates with Canadian academic and medical institutions. Avicanna has established a scientific platform including research and development and clinical development which led to the commercialization of more than twenty products across four main market segments.